Compare · OBIO vs RLX
OBIO vs RLX
Side-by-side comparison of Orchestra BioMed Holdings Inc. (OBIO) and RLX Technology Inc. (RLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OBIO and RLX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $2.77B, about 8.6x OBIO ($322.2M).
- OBIO has been more active in the news (8 items in the past 4 weeks vs 4 for RLX).
- OBIO has more recent analyst coverage (9 ratings vs 2 for RLX).
- Company
- Orchestra BioMed Holdings Inc.
- RLX Technology Inc.
- Price
- $5.36-1.65%
- $1.79-1.10%
- Market cap
- $322.2M
- $2.77B
- 1M return
- +40.68%
- -
- 1Y return
- +79.26%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- 2021
- News (4w)
- 8
- 4
- Recent ratings
- 9
- 2
RLX
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
Latest OBIO
- Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
- Director Mack John Prosper covered exercise/tax liability with 4,885 shares, decreasing direct ownership by 7% to 66,544 units (SEC Form 4) (tax liability)
- Director Fain Eric S covered exercise/tax liability with 5,145 shares (SEC Form 4) (withholding obligation)
- Director Pacitti David covered exercise/tax liability with 3,761 shares, decreasing direct ownership by 6% to 54,750 units (SEC Form 4) to satisfy withholding tax
- Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form 10-Q filed by Orchestra BioMed Holdings Inc.
- Officer Sherman Darren sold $61,350 worth of shares (15,000 units at $4.09) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,154,327 units (SEC Form 4)
- SEC Form 144 filed by Orchestra BioMed Holdings Inc.
- Officer Sherman Darren sold $64,050 worth of shares (15,000 units at $4.27) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,169,327 units (SEC Form 4)
- SEC Form 144 filed by Orchestra BioMed Holdings Inc.
Latest RLX
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited Second Quarter 2026 Financial Results
- RLX Technology to Report Second Quarter 2026 Financial Results on August 14, 2026
- SEC Form 4 filed by Chief Financial Officer Lu Chao
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited First Quarter 2026 Financial Results
- RLX Technology to Report First Quarter 2026 Financial Results on May 20, 2026
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate